New Two-Drug attack on tough breast cancer enters final testing phase
NCT ID NCT07382687
Summary
This study is for women with a specific, hard-to-treat type of advanced breast cancer that has grown despite standard hormone and CDK4/6 inhibitor therapy. It will test if adding a drug called famitinib to another drug (SHR-A1811) works better and is safe compared to using SHR-A1811 alone. The main goal is to see if the combination can keep the cancer from growing for a longer period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.